From clinical research and patient support to partnerships that address gaps in care, UCB Canada reflects on two decades of growth and looks to its next chapter

Reimbursement decision provides eligible Ontarians living with generalized myasthenia gravis with an additional treatment option that may offer greater flexibility, independence, and individualized care.

^PrRYSTIGGO® (rozanolixizumab injection) and ^PrZILBRYSQ® (zilucoplan injection) are now publicly reimbursed in multiple provinces in Canada, as well as through Veterans Affairs Canada and the Non-Insured Health Benefits Program.

Following an examination of clinical evidence and stakeholder input, Canada’s Drug Agency (CDA-AMC) has recommendedBIMZELX® (bimekizumab injection) for reimbursement with conditions for patients with moderate to severe hidradenitis suppurativa. 

UCB, a global biopharmaceutical company committed to improving the lives of people with severe diseases, announced the expansion of its FASTRAX Canada program into Québec City.

Receives Positive Reimbursement Recommendation from INESSS for Adults Living with Moderate to Severe Hidradenitis Suppurativa (HS)